title: Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.
authors.affiliation: Department of Nephrology, Boston University School of Medicine, Boston, Massachusetts.|Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts.
authors.forename: Andrea
authors.initials: A
authors.lastname: Havasi
authors.affiliation: Department of Nephrology, Boston University School of Medicine, Boston, Massachusetts.|Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts.
authors.forename: Lauren
authors.initials: L
authors.lastname: Stern
authors.affiliation: Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts.
authors.forename: Stephen
authors.initials: S
authors.lastname: Lo
authors.affiliation: Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
authors.forename: Fangui
authors.initials: F
authors.lastname: Sun
authors.affiliation: Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts. vaishali.sanchorawala@bmc.org.|Section of Hematology-Oncology, Boston University School of Medicine, Boston, Massachusetts. vaishali.sanchorawala@bmc.org.
authors.forename: Vaishali
authors.initials: V
authors.lastname: Sanchorawala
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D000075363:Immunoglobulin Light-chain Amyloidosis / Q000175:diagnosis* / Q000628:therapy*; D007668:Kidney / Q000473:pathology*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D009367:Neoplasm Staging; D033581:Stem Cell Transplantation / Q000379:methods*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan